Esperion Therapeutics (ESPR) Non-Current Assets (2012 - 2026)

Esperion Therapeutics has reported Non-Current Assets for 15 years, with the latest figure at $3.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets fell 41.57% year-over-year to $3.1 million; the trailing twelve-month figure through Mar 2026 stood at $14.4 million (down 41.92% YoY), and the FY2025 full-year result was $3.3 million, down 43.05% from the prior year.
• Non-Current Assets for Q1 2026 stood at $3.1 million, down from $3.3 million in the prior quarter.
• The five-year high for Non-Current Assets was $52.0 million in Q1 2022, with the low at $1.2 million in Q1 2023.
• Historically, Non-Current Assets has averaged $12.6 million across 5 years, with a median of $4.7 million in 2023.
• Annual changes were most pronounced in 2022 — Non-Current Assets jumped 874.13% — and 2023, when it sank 97.67%.
• Esperion Therapeutics' Non-Current Assets stood at $1.3 million in 2022, then surged by 276.67% to $4.7 million in 2023, then advanced by 23.08% to $5.8 million in 2024, then plunged by 43.05% to $3.3 million in 2025, then dropped by 7.48% to $3.1 million in 2026.
• The last three Non-Current Assets figures came in at $3.1 million (Q1 2026), $3.3 million (Q4 2025), and $3.6 million (Q3 2025), per Business Quant data.